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Background: Although octogenarians constitute a fast-growing portion of cardiovascular patients, few data are
available on the outcome of patients aged ≥85 years with ST-Elevation Myocardial Infarction (STEMI).
Methods and Results:Weanalyzed126 consecutive patients aged ≥85 years (age 88±2years)with STEMI, under-
going primary percutaneous coronary intervention (pPCI) within 12 hours from symptoms onset.
Long-term follow-up (median 898 days) was obtained for the 102 patients surviving the index-hospitalization.
In-hospital mortality rate was 19%. Nonagenarians, diabetes mellitus, severe left ventricular systolic dysfunction
and intra-aortic balloon pumping were signiﬁcantly and independently correlated to in-hospital mortality at the
multivariate analysis. A low rate of complications was detected. Among patients surviving the index hospitaliza-
tion, 32 (31%) patients died during follow-up. 55 patients (54%) had re-hospitalization due to cardiovascular
causes. The univariate analysis identiﬁed chronic renal failure, Killip class ≥ 3, TIMI Risk Score N8 and very high
risk of bleeding as predictors of long-termoverall mortality. At themultivariate analysis only chronic renal failure
and very high risk of bleeding were signiﬁcantly and independently correlated to long-term all-cause mortality.
Renal function and anteriormyocardial infarctionwere signiﬁcantly and independently associatedwith the com-
bined end-point of cardiac mortality and re-hospitalization due to cardiovascular disease at the multivariate
analysis.
Conclusions: PPCI in patients ≥85 years old is relatively safe. In this population, pPCI is associated with a good
long-term survival, although still worse than in younger patients, despite a considerable incidence of re-




Primary percutaneous coronary intervention
Long-term outcome
1. Introduction
The fastest growing segment of the western world population is the
oldest old (age ≥ 85 years); in these subjects, the prevalence of coronary
artery disease is high and age itself is a predictor of adverse events after
acute coronary syndrome (ACS) [1–6]. However, elderly patients are
underrepresented in clinical trials of ACS [1] or primary percutaneous
coronary intervention (pPCI) [2–5,7,8]. Elderly patients with ST-
segment elevation myocardial infarction (STEMI) are less likely to
receive an invasive treatment due to the perception of poor outcome
and often have atypical symptoms that cause longer delay to presenta-
tion and treatment,more adverse events and prolonged hospital stay [5,
9–11].
The majority of studies considered 75 years as age cut-off while the
treatment and outcome of very-old patients (over 85 years old) are still
poorly analyzed, especially longterm mortality and rehospitalizations.
Based on these considerations, we conducted a retrospective obser-
vational study to evaluate the short and long-term outcome of consecu-
tive unselected patients aged ≥85 years with STEMI referred to pPCI.
2. Methods
From January 2007 to December 2013, a total of 126 patients aged
≥85 years with STEMI, admitted to the coronary care units of “Azienda
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2Sanitaria Universitaria Integrata” of Udine and Trieste, were registered
into a local medical registry.
Diagnosis of STEMI was made on the basis of typical ECG chang-
es and/or ischemic chest pain associated with elevation of cardiac
biomarkers [12]. All patients underwent immediate coronary angi-
ography and pPCI. Patients with contraindications to coronary an-
giography and pPCI, such as active bleeding and/or very severe
comorbidities (e.g. known terminal illness), were not included in
the study.
According to guidelines [13–15], all included patients received aspi-
rin (250–300 mg), clopidogrel (300–600 mg) and intravenous heparin
during the transport or at the arrival at the pPCI-center. Interventional
strategy, stent selection and use of GPIIb/IIIa inhibitors were according
to local standard practice. Post-procedural antiplatelet therapy included
lifelong aspirin (100 mg/day) and clopidogrel (75 mg/day) for 1 to
12 months.
Detailed demographic, clinical, laboratory, echocardiographic, an-
giographic and procedural information was retrieved from the hospital
databases and patient records. Follow-up datawere obtained from a Re-
gional Registry, which holds information on discharge diagnoses of all
hospitalizations according to International Classiﬁcation of Disease
codes.
The following clinical endpoints were evaluated during the index
hospitalization: death, re-infarction (deﬁned as an increase in troponin
associated to symptoms or electrocardiographic alterations) or re-
revascularization (deﬁned as the requirement for urgent repeat PCI or
emergency coronary artery bypass graft), heart failure, arrhythmias,
bleeding complications, cerebrovascular accident and contrast-
induced nephropathy.
Global Utilization of Streptokinase and Tissue Plasminogen Activity for
Occluded Coronary Arteries (GUSTO) classiﬁcation for bleeding was
adopted while Thrombolysis In Myocardial Infarction risk Score (TIMI
risk Score) and Can Rapid risk stratiﬁcation of Unstable angina patients
Suppress ADverse outcomes with Early implementation of the ACC/AHA
Guidelines (CRUSADE) score were utilized for risk stratiﬁcation
[16–18]. A cutoff of 40 (high risk) or 50 (very high risk) points for
CRUSADE score, 8 points for TIMI Risk Score and 3 for the killip class
were used to identify a subpopulation at high risk.
Cardiogenic shockwas determined to be present using conventional
clinical criteria of hypotension and signs of peripheral hypoperfusion
that did not rapidly resolve. Successful percutaneous coronary interven-
tion (PCI) was deﬁned as the achievement of Thrombolysis InMyocardial
Infarction (TIMI) grade 3 ﬂowwith b30% residual stenosis. The estimat-
ed glomerular ﬁltration rate (eGFR) was calculated using the abbreviat-
ed Modiﬁcation of Diet in Renal Disease formula (MDRD) [19] and the
creatinine level measured on admission. A cutoff of eGFR ≤60 mL/min/
1.73 mq was used to identify patients with relevant chronic renal
failure.
Contrast induced nefropathy (CIN)was deﬁned as acute kidney inju-
ry occurring after intravenous contrast administration, measured as a
25% increase in serum creatinine from baseline or 0.5 mg/dL increase
in absolute value.
Severe left ventricular dysfunction was deﬁned as ejection fraction
≤35%.
The primary follow-up clinical endpoint was deﬁned as the occur-
rence of death. The secondary follow-up clinical endpoint was deﬁned
as a composite of cardiac death and re-hospitalization for cardiovascular
causes (recurrent myocardial ischemic events, heart failure and cere-
brovascular accident).
2.1. Statistical methods
Continuous variables are expressed as mean and standard deviation
(SD) or median and interquartile range (IQR) as appropriate. Categori-
cal data are presented as absolute numbers and percentages.
Chi-square test or Mann-Whitney test were used as appropriate to
compare the two groups for categorical and continuous variables
respectively.
Univariate andmultivariate Cox proportional hazards analyses were
used to test the association between the primary and secondary follow-
up clinical endpoint and baseline covariates. Clinically relevant variables
or those associated with a univariate p b 0.1 were included in multivar-
iate models. Backward stepwise regression method was used. Survival
curves were generated by the Kaplan–Meier method. Two-tailed tests
were considered statistically signiﬁcant at the 0.05 level.
All statistical analyses were performed using SPSS 20 (IBM SPSS Sta-
tistics for Windows, Version 20.0. Armonk, NY: IBM Corp.)
3. Results
Demographic and clinical characteristics, angiographic and proce-
dural data and mortality of the study population in comparison with
younger contemporary cohort are presented in Table 1. In very-old pa-
tients, a higher prevalence of female gender, hypertension, chronic
renal failure and minor use of radial approach and Glycoprotein IIb/IIIa
inhibitors were observed. Moreover, very-old patients were signiﬁcant-
ly less likely to be smokers than younger ones butwithmore prevalence
of diabetes, severe left ventricular dysfunction and killip class ≥ 3 at ad-
mission. In addition, Door-to-balloon time and ischemia time were
slightly longer in very elderly patients compared to younger patients.
The rates of in-hospital and longtermmortality were signiﬁcantly supe-
rior for very-elderly patients compared to younger patients.
Table 2 describes the in-hospital outcome and the dischargemedical
therapy. Median length of hospital stay was 7 days (interquartile range
5 to 11). Twenty-four (19%) patients died during the index hospitaliza-
tion. Vascular access-related complications occurred in 12 (10%) pa-
tients: three patients required surgical repair (due to intestinal
ischemia or severe bleeding) and died during the index hospitalization,
while the remaining patients had small groin hematomas without he-
modynamic compromise. None had intracranial hemorrhage or cardiac
tamponade.Moderate bleeding requiring haemotransfusion occurred in
2 patients (2%). 3 (2%) patients experienced a cerebrovascular accident
during the index hospitalization: 2 patients had an ischemic stroke
while one patient had a transient ischemic attack. Contrast-induced ne-
phropathy after PCI occurred in 12 (10%) patients and one of them re-
quired dialysis. Stent thrombosis was observed in one patient (0,8%).
Table 3 shows the results of the univariate andmultivariate Cox pro-
portional Hazards Analyses performed to determine predictors of in-
hospital mortality, of the primary and secondary follow-up clinical end-
point (i.e. all-cause mortality and cardiac mortality & re-hospitalization
for cardiovascular causes).
Age ≥ 90 years (p=0.015), Killip class ≥ 3 at admission (p=0.021),
time from symptoms onset to PCI (p=0.045), TIMI Risk Score N 8 (p=
0.008), high risk of bleeding (p= 0.047), left ventricular function (p b
0.001), intra-aortic balloon pumping (p= 0.005) and PCI failure (p=
0.007) were all signiﬁcantly related to in-hospital mortality at the uni-
variate analysis. Nonagenarians, diabetes mellitus, severe left ventricu-
lar systolic dysfunction and intra-aortic balloon pumping were
signiﬁcantly and independently correlated to in-hospital mortality at
the multivariate analysis.
The median duration of follow-up of patients who survived at
index hospitalization was 898 days (IQR 436–1427 day). Among
the 102 patients surviving the index hospitalization, the overall mor-
tality rate was 31% (32 patients) while the cardiac mortality rate was
16.7% (17 patients). A total of 55 (53,9%) patients had at least one
hospitalization for cardiovascular causes during follow-up: 19 pa-
tients had recurrentmyocardial ischemic events (i.e. unstable angina
or myocardial infarction), 30 patients had ≥1 hospitalization for heart
failure, 4 patients were re-admitted because of a stroke and 2 patient
had arrhytmias.
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3Chronic renal failure (p = 0.002), Killip class ≥ 3 (p = 0.037),
TIMI Risk Score N 8 (p = 0.013) and very high risk of bleeding (p
= 0.02) were signiﬁcantly related with the primary follow-up
clinical endpoint at the univariate analysis. At the multivariate
analysis only chronic renal failure and very high risk of bleeding
were signiﬁcantly and independently correlated to long-term all-
cause mortality.
Renal function (p = 0.038), anterior myocardial infarction (p =
0.001) and severe left ventricular dysfunction (p= 0.016) were signif-
icantly associated with the secondary follow-up clinical endpoint at the
Table 1
Baseline characteristics, angiographic and procedural data, in-hospital and longterm mortality and Kaplan-Meier curve of overall survival separated by age groups.
Age group (years) p-Value
≥85 (n= 126) 75–85 (n= 485) b75 (n= 1723) G1 vs G2 G1 vs G3
Age (years) 88 ± 2 79 ± 3 60 ± 10 b0.001 b0.001
Nonagenarians 30 (24%)
Male 53 (42%) 280 (58%) 1441 (84%) 0.001 b0.001
Diabetes mellitus 31 (25%) 109 (22%) 251 (15%) 0.761 0.031
Arterial hypertension 92 (73%) 314 (65%) 856 (50%) 0.023 b0.001
Hypercholesterolemia 45 (36%) 180 (37%) 797 (46%) 0.069 b0.001
Smoker 31 (25%) 110 (23%) 879 (51%) 0.761 b0.001
Previous cerebrovascular accidents 10 (8%)
Peripheral artery disease 7 (6%)
Haemoglobin (g/dL) 12 (11−13)
eGFR (mL/min/1,73 m2) 56 (50–71)
Chronic renal failure (eGFR ≤60 mL/min/1,73 m2) 63 (50%) 67 (14%) 82 (5%) b0.001 b0.001
Previous myocardial infarction 16 (13%) 60 (12%) 169 (10%) 0.943 0.359
Previous PCI 5 (4%) 14 (3%) 51 (3%) 0.746 0.793
Previous CABG 6 (5%) 9 (2%) 11 (1%) 0.365 0.001
Anterior STEMI 64 (51%) 229 (47%) 743 (43%) 0.449 0.079
Heart rate (bpm) 73 ± 19 75 ± 20 75 ± 28 0.559 0.384
Systolic blood pressure (mmHg) 130 ± 31 139 ± 91 136 ± 31 0.850 0.622
Killip class ≥ 3 18 (14%) 62 (13%) 98 (6%) 0.971 0.002
Cardiogenic shock 12 (10%)
Right ventricular involvement 8 (6%) 24 (5%) 64 (4%) 0.530 0.909
Cardiac arrest 5 (4%)
TIMI Risk Score 6 (5–7)
TIMI Risk Score N 8 18 (14%)
CRUSADE Score 47 ± 13
CRUSADE Score N 40 (high risk) 69 (55%)
CRUSADE Score N 50 (very high risk) 40 (32%)
Left ventricular ejection fraction (%) 47 ± 12
Severe left ventricular systolic dysfunction (EF ≤35%) 24 (19%) 56 (12%) 91 (5%) 0.396 b0.001
Moderate or severe aortic stenosis 13 (10%)
Moderate or severe mitral regurgitation 17 (13%)
Advanced atrioventricular block 15 (12%)
Time from symptoms to initial hospital arrival - prehospital delay (min) 110 (66–199) 102 (55–195) 85 (45–158) 0.879 0.030
Door-to-balloon time (min) 100 (75–134) 98 (72–135) 90 (68–118) 0.641 0.008
Time from symptoms to PCI (min) 216 (158–318) 226 (158–336) 191 (141–281) 0.767 0.015
Ischemia time ≤ 3 h 38 (30%)
Radial approach 20 (16%) 120 (25%) 551 (32%) 0.021 b0.001
Infarct-related coronary artery
• Left anterior descending 58 (46%) 216 (45%) 722 (42%) 0.862 0.290
• Right coronary artery 43 (34%) 163 (34%) 607 (35%) 0.914 0.978
• Left circumﬂex artery 12 (10%) 73 (15%) 321 (19%) 0.371 0.076
• Left main coronary artery 3 (2%)
• Graft 3 (2%)
• Other vessel 7 (6%)
Multivessel coronary disease 76 (60%) 279 (58%) 819 (48%) 0.074 b0.001
Severe Left main coronary artery disease 14 (11%)
PCI 126 (100%)
PCI with stent 117 (93%)
PCI with DES 7 (6%)
Number of stents per patient 1 (1–2)
Thrombus aspiration 71 (56%)
IABP 11 (9%)
Endotracheal Intubation 4 (3%)
Temporary transvenous pacemaker 10 (8%)
Glycoprotein IIb/IIIa inhibitors 13 (10%) 126 (26%) 672 (39%) b0.001 b0.001
Successful PCI 103 (82%)
In-hospital death 24 (19%) 45 (9%) 55 (3%) 0.002 b0.001
Longterm all-cause death 56 (44%) 149 (31%) 151 (9%) 0.007 b0.001
Data are expressed as mean ± SD or median (interquartile range) and numbers (percentages).
Intra-aortic balloon counterpulsation was required because of hemodynamic instability or high-risk procedure (left main or 3-vessel disease). CABG= Coronary artery bypass graft sur-
gery; CRUSADE= Can Rapid risk stratiﬁcation of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines; DES= drug-eluting stent;
EF= Ejection fraction; eGFR= estimated glomerular ﬁltration rate; IABP= intra-aortic balloon pumping; PCI = percutaneous coronary intervention; STEMI= ST-Elevation Myocardial
Infarction; TIMI = Thrombolysis In Myocardial Infarction.
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4univariate analysis. At the multivariate analysis only renal function and
anterior myocardial infarction were signiﬁcantly and independently
correlated to long-term cardiacmortality and re-hospitalization for car-
diovascular causes.
4. Discussion
With the increasing of the older population, the burden of acute
myocardial infarction will gain more importance. Morbidity and
mortality rates in patients with STEMI increase indeed with age;
in particular, mortality of older patients is still higher than in
younger patients even after implementation of an infarction net-
work [5,7].
According to current guidelines of the AHA/ACC [14], patients with
STEMI presenting within 12 h from symptom onset should be treated
with reperfusion therapy; pPCI seems to be the most effective and safe
reperfusion strategy in elderly patients with STEMI, but few data de-
scribe the subgroup of the oldest old [2–4,8,20–22]. Although there is
a great interest in elderly population, themajority of studies considered
indeed 75 years as age cut-off while the treatment and outcomeof very-
old patients (over 85 years old) are still poorly analyzed.
A summary of the results of the previously published observational
studies in very-old patients is presented in Table 4.
Elderly patients with STEMI have been reported to have high
mortality rates: published data suggest that mortality ranges from
10% to 25% in hospital and from 19% to 52% at 1 year, with the highest
mortality seen in patients treated with conservative therapies [16,
18,22–37].
In the current study, overall in-hospital mortality rate was 19%, con-
sistent with previous observations [26,29,35,36,38]. Several variables
were signiﬁcantly related to in-hospital mortality: Killip class ≥ 3,
age ≥ 90 years and PCI failure were correlated to worst in-
hospital outcome, similarly to previous studies [26,35,37]. Howev-
er the prevalence of in-hospital death in the subgroup with cardio-
genic shock was unexpectedly lower than previously reported
(42% in our study while in literature is 54–90%) [26,29,36]. Ische-
mic time was also correlated to in-hospital death, underlying the
difﬁculty in the management of these patients that often have atypical
symptoms with longer delay to presentation. Other variables signiﬁ-
cantly related to in-hospital death were TIMI Risk Score N 8, high risk
of bleeding, severe left ventricular dysfunction along with intra-aortic
balloon pumping (IABP), which clearly identify a high risk subgroup.
Among these variables only nonagenarians, diabetes mellitus, severe
left ventricular systolic dysfunction and intra-aortic balloon pumping
were signiﬁcantly and independently correlated to in-hospital mortali-
ty at the multivariate analysis.
A low use of radial access as well as of drug-eluting stent (DES) and
Glycoprotein IIb/IIIa inhibitors in old patients were documented in our
centers, like in other studies [35,38]. During the study period, coronary
angiographywas performedby femoral access in nearly all cases, as pre-
ferred puncture site for PCIp in our centers. Due to an high use of femo-
ral access, a relevant rate of vascular access-related complications (10%)
were observed which required surgical repair in 25% of cases. The low
use of DES and Glycoprotein IIb/IIIa inhibitors reﬂects the widespread
perception of the higher risk of bleeding in elderly patients and the re-
luctance of operators to commit elderly patients to dual antiplatelet
therapy for a prolonged period. The association of older age and the fre-
quency of haemorrhagic complications of PCI are also well known
[39–42]. However, in literature there are different results as regards
bleeding complications in elderly: in-hospital major bleeding ranging
from 0.1% to 18% depending on different authors [22,25,28,29,43].
Moreover, it is interesting to note that the stroke rate in elderly pPCI pa-
tients seems to be lower inmore recent studies [29,35,38], varying from
0.85% to 3%. Furthermore, Murphy et al. [34] underlined a higher rate of
acute kidney injury in the elderly (≥ 80 years old) cohort than in youn-
ger patients (12.9% vs. 4.0%). A similar rate (10%) was found in elderly
patients also by Valente et al. [26]. In our study a low rate of complica-
tionswere detected, in particular inmajor bleedings (2%) or cerebrovas-
cular accidents (2%); only one patient suffered stent thrombosis (0,8%)
while contrast induced nephropathy after PCI occurred in 10% of
patients.
It was found that thosewho survived to hospital discharge had a rea-
sonable chance for long-term survival with a long-term mortality rate
lower than reported by other authors [26,27,29,35,37]. Infact, our 1-
year overall mortality rate was 14%with a total of 9.8% because of cardi-
ac causes, while long-term overall mortality were 31% with a total of
long-term cardiovascular mortality of 16.7%. Chronic renal failure and
very high risk of bleeding were identiﬁed as independent predictors
for long-term overall mortality at the multivariate analysis. Despite a
good survival rate, a considerable number of hospitalizations due to
cardiovascular events were observed, especially due to recurrent
myocardial ischemic events and heart failure. Renal function and
anterior myocardial infarction were signiﬁcantly and independently
correlated with the combined end-point of cardiac mortality and re-
hospitalization due to cardiovascular diseases at the multivariate
analysis.
On the basis of our data and other studies [6,21,22,25–27,33,37],
older STEMI patients can receive similar care to younger patients. A
PCI-based strategy is preferred in elderly patients with STEMI and
rapid transfer for pPCI (in combination with appropriate adjunctive
pharmacology) produced improved outcomes, although still worse
than in younger patients. According to other authors, our study con-
ﬁrms that patients selection through clinical evaluation is important to
be done before acceptance for pPCI: clinical characteristics have been
shown to be more predictive of adverse outcomes than procedural fac-
tors [6,22,44,45].
Table 2
In-hospital events and discharge medical therapy.
In-hospital events
Hospital stay (days) 7 (5–11)
Residual angina 2 (2%)
Re-infarction 1 (1%)
Heart failure 20 (16%)
Arrhythmias 31 (25%)
• Atrial ﬁbrillation 14 (45%)
• Ventricular tachycardia 7 (23%)
• Atrioventricular block 2 (6%)
• Ventricular ﬁbrillation 4 (13%)
• Asystolia 1 (3%)
• Unknown 3 (10%)
Stroke 2 (2%)
TIA 1 (1%)
Severe bleedings 2 (2%)
Moderate bleedings (requiring transfusion) 2 (2%)
Mild bleedings 8 (6%)
Vascular access-related complications 12 (10%)




Contrast induced nephropathy 12 (10%)









Missing values about discharge medical therapy 17 (17%)a
Data are expressed asmean± SD or median (interquartile range) and numbers (percent-
ages). TIA = Transient Ischemic Attack.
a Percentage calculated on patients surviving the index hospitalization (n= 102).
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55. Study limitations
As observational retrospective registry, our study lacks of some data
usefull to better stratify the frailty of the elderly patients and it is affect-
ed by selection bias because the treatment strategy was deﬁned by
clinicians.
6. Conclusion
In conclusion, our data suggest that patients aged ≥85 years with
STEMI can be safely transferred to tertiary care centers for timely pPCI,
with a low rate of PCI failure, but with an adeguate clinical evaluation
before acceptance for coronary angiography. On the other hand, pPCI
is less able to affect the poor prognosis for very old patients with cardio-
genic shock.
Furthermore, those who survived to hospital discharge had a rea-
sonable chance for long-term survival, although still worse than youn-
ger patients, despite a considerable incidence of re-hospitalization due
to cardiovascular events.
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Table 3
Univariate and multivariate Cox proportional Hazards Analyses for in-hospital mortality, for long-term all-cause mortality and for the combined endpoint of long-term cardiac mortality
and re-hospitalization for cardiovascular causes.
Univariate Multivariate
In-hospital mortality
HR 95% IC P value HR 95% IC P value
Female 0.778 0.348–1.739 0.541 – – –
Age ≥ 90 years 2.748 1.218–6.203 0.015 3.361 1.182–9.556 0.023
Diabetes mellitus 2.169 0.947–4.967 0.067 3.490 1.172–10.390 0.025
Chronic renal failure (eGFR ≤60 mL/min/1,73 m2) 1.476 0.611–3.564 0.386 – – –
Killip class ≥ 3 2.884 1.173–7.091 0.021 – – –
Cardiogenic shock 2.534 0.943–6.813 0.065 – – –
Ischemia time (min) 1.002 1.000–1.005 0.045 – – –
TIMI Risk Score N 8 3.169 1.353–7.419 0.008 – – –
high risk of bleeding (CRUSADE Score N 40) 7.641 1.032–56.585 0.047 – – –
Anterior STEMI 1.939 0.829–4.536 0.127 – – –
EF 0.927 0.890–0.966 b0.001
Severe left ventricular systolic dysfunction (EF ≤35%) 2.004 0.853–4.707 0.111 4.598 1.550–13.641 0.006
Multivessel coronary disease 0.949 0.421–2.141 0.900 – – –
IABP 3.793 1.500–9.590 0.005 3.629 1.085–12.134 0.036
Advanced atrioventricular block 2.311 0.860–6.209 0.097 – – –
PCI failure 3.041 1.349–6.856 0.007 – – –
Long-term all-cause mortality
HR 95% IC P value HR 95% IC P value
Female 0.803 0.400–1.614 0.538 0.500 0.213–1.170 0.110
chronic renal failure 3.766 1.605–8.835 0.002 3.966 1.452–10.834 0.007
Killip class ≥ 3 2.623 1.062–6.480 0.037 – – –
TIMI Risk Score N 8 3.099 1.264–7.598 0.013 – – –
very high risk of bleeding (CRUSADE Score N 50) 2.336 1.144–4.770 0.020 3.467 1.422–8.452 0.006
Diabetes mellitus 1.761 0.808–3.837 0.155 – – –
Anterior STEMI 1.401 0.692–2.835 0.349 – – –
Multivessel coronary disease 1.042 0.508–2.136 0.912 – – –
Severe Left main coronary artery disease 1.607 0.560–4.612 0.378 – – –
Severe left ventricular systolic dysfunction (EF ≤ 35%) 1.748 0.713–4.285 0.222 – – –
Nonagenarians 1.125 0.459–2.756 0.797 – – –
Any relevant valvulopathy 1.288 0.575–2.883 0.539 – – –
Time from symptoms to PCI (min) 0.999 0.997–1.002 0.608 – – –
Successful PCI 0.355 0.084–1.494 0.158 – – –
Long-term cardiac mortality and re-hospitalization for cardiovascular causes
HR 95% IC P value HR 95% IC P value
Female 0.704 0.420–1.180 0.183 – – –
eGFR (MDRD) 0.985 0.970–0.999 0.038 0.986 0.970–1.002 0.076
Anterior STEMI 2.456 1.447–4.169 0.001 2.431 1.310–4.512 0.005
Severe left ventricular systolic dysfunction (EF ≤ 35%) 2.216 1.163–4.221 0.016 1.907 0.874–4.161 0.105
Nonagenarians 1.603 0.855–3.006 0.141 1.845 0.928–3.669 0.081
Any relevant valvulopathy 1.593 0.899–2.824 0.111 – – –
Time from symptoms to PCI (min) 0.998 0.996–1.000 0.130 0.998 0.996–1.000 0.069
Successful PCI 1.724 0.737–4.037 0.209 – – –
Multivessel coronary disease 0.929 0.548–1.573 0.783 – – –
Severe Left main coronary artery disease 1.165 0.463–2.934 0.745 – – –
Diabetes mellitus 1.129 0.606–2.102 0.703 – – –
TIMI Risk Score N 8 1.748 0.790–3.870 0.168 – – –
very high risk of bleeding (CRUSADE Score N 50) 0.998 0.589–1.693 0.995 – – –
CRUSADE= Can Rapid risk stratiﬁcation of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines; EF= Ejection fraction; eGFR=
estimated glomerular ﬁltration rate; IABP= intra-aortic balloon pumping; MDRD=Modiﬁcation of Diet in Renal Disease; PCI = percutaneous coronary intervention; STEMI = ST-Ele-
vation Myocardial Infarction; TIMI = Thrombolysis In Myocardial Infarction.
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